We are analyzing https://link.springer.com/article/10.1186/1741-7015-10-51.

Title:
Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration | BMC Medicine
Description:
Background The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) checklist consists of 20 items to report for published tumor marker prognostic studies. It was developed to address widespread deficiencies in the reporting of such studies. In this paper we expand on the REMARK checklist to enhance its use and effectiveness through better understanding of the intent of each item and why the information is important to report. Methods REMARK recommends including a transparent and full description of research goals and hypotheses, subject selection, specimen and assay considerations, marker measurement methods, statistical design and analysis, and study results. Each checklist item is explained and accompanied by published examples of good reporting, and relevant empirical evidence of the quality of reporting. We give prominence to discussion of the
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,603,724 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

pubmed, marker, google, scholar, prognostic, cancer, studies, patients, variables, study, data, analysis, reporting, model, cas, tumor, item, results, analyses, clinical, survival, markers, time, methods, information, size, reported, models, outcome, multivariable, report, missing, breast, standard, central, remark, treatment, continuous, important, sample, altman, authors, effect, regression, explanation, performed, values, effects, review, clin,

Topics {✒️}

dcc [dextran-coated charcoal] nci-eortc international meeting gov/global/pdfs/nci_best_practices_060507 health-research-reporting/reporting-guidelines/remark estrogen receptor-alpha phosphorylation technology-sponsored consensus workshop cytoplasmic p21waf1/cip1 expression reverse kaplan-meier method node-negative breast cancer node-positive breast cancer parallel-group randomized trials wilcoxon rank-sum test post-operative adjuvant therapies standard kaplan-meier method kaplan-meier survival curves plot kaplan-meier estimates flexible parametric proportional-hazards van de vijver fractional polynomial time-transformation neoadjuvant-treated gastric carcinoma homozygous wild-type genotype shorter disease-free survival' untreated primary cn-aml international conference calls prior cancer-directed therapies s-phase fraction determined org/resource-centre/library publishing research involving smad4 gene mutations estrogen-dependent prognostic significance paraffin-embedded] tissue sections early-stage breast cancer tables showing cross-classifications iii gastric carcinoma stem-cell mobilization cambridge university press muller-hermelink hk accept disease-free survival article download pdf invasive breast cancer rigorous prospective-retrospective validation meijer-van gelder de stavola bl n0 versus n1-3 male versus female privacy choices/manage cookies data-dependent model building data-dependent modeling steps committee initially convened reported health-related quality

Questions {❓}

Altman DG, Royston P: What do we mean by validating a prognostic model?
Carpenter J, Bithell J: Bootstrap confidence intervals: when, which, what?
Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, Manegold C, Coens C, Giaccone G, Van Meerbeeck J, EORTC Lung Cancer Group and Qualoty of Life Unit: Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients?
Gill S, Sargent D: End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?
McShane LM, Altman DG, Sauerbrei W: Identification of clinically useful cancer prognostic factors: what are we missing?
Royston P, Sauerbrei W, Ritchie A: Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma?
Vandenbroucke JP: Prospective or retrospective: what's in a name?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
         description:The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) checklist consists of 20 items to report for published tumor marker prognostic studies. It was developed to address widespread deficiencies in the reporting of such studies. In this paper we expand on the REMARK checklist to enhance its use and effectiveness through better understanding of the intent of each item and why the information is important to report. REMARK recommends including a transparent and full description of research goals and hypotheses, subject selection, specimen and assay considerations, marker measurement methods, statistical design and analysis, and study results. Each checklist item is explained and accompanied by published examples of good reporting, and relevant empirical evidence of the quality of reporting. We give prominence to discussion of the 'REMARK profile', a suggested tabular format for summarizing key study details. The paper provides a comprehensive overview to educate on good reporting and provide a valuable reference for the many issues to consider when designing, conducting, and analyzing tumor marker studies and prognostic studies in medicine in general. To encourage dissemination of the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration, this article has also been published in PLoS Medicine.
         datePublished:2012-05-29T00:00:00Z
         dateModified:2012-05-29T00:00:00Z
         pageStart:1
         pageEnd:39
         license:http://creativecommons.org/licenses/by/2.0
         sameAs:https://doi.org/10.1186/1741-7015-10-51
         keywords:
            Overall Survival
            Multivariable Model
            Standard Variable
            Prognostic Study
            Selective Reporting
            Medicine/Public Health
            general
            Biomedicine
         image:
         isPartOf:
            name:BMC Medicine
            issn:
               1741-7015
            volumeNumber:10
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Douglas G Altman
               affiliation:
                     name:University of Oxford
                     address:
                        name:Centre for Statistics in Medicine, University of Oxford, Oxford, UK
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Lisa M McShane
               affiliation:
                     name:US National Cancer Institute
                     address:
                        name:US National Cancer Institute, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Willi Sauerbrei
               affiliation:
                     name:Universitaetsklinikum Freiburg
                     address:
                        name:Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sheila E Taube
               affiliation:
                     name:ST-Consulting
                     address:
                        name:ST-Consulting, Bethesda, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
      description:The Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) checklist consists of 20 items to report for published tumor marker prognostic studies. It was developed to address widespread deficiencies in the reporting of such studies. In this paper we expand on the REMARK checklist to enhance its use and effectiveness through better understanding of the intent of each item and why the information is important to report. REMARK recommends including a transparent and full description of research goals and hypotheses, subject selection, specimen and assay considerations, marker measurement methods, statistical design and analysis, and study results. Each checklist item is explained and accompanied by published examples of good reporting, and relevant empirical evidence of the quality of reporting. We give prominence to discussion of the 'REMARK profile', a suggested tabular format for summarizing key study details. The paper provides a comprehensive overview to educate on good reporting and provide a valuable reference for the many issues to consider when designing, conducting, and analyzing tumor marker studies and prognostic studies in medicine in general. To encourage dissemination of the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration, this article has also been published in PLoS Medicine.
      datePublished:2012-05-29T00:00:00Z
      dateModified:2012-05-29T00:00:00Z
      pageStart:1
      pageEnd:39
      license:http://creativecommons.org/licenses/by/2.0
      sameAs:https://doi.org/10.1186/1741-7015-10-51
      keywords:
         Overall Survival
         Multivariable Model
         Standard Variable
         Prognostic Study
         Selective Reporting
         Medicine/Public Health
         general
         Biomedicine
      image:
      isPartOf:
         name:BMC Medicine
         issn:
            1741-7015
         volumeNumber:10
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Douglas G Altman
            affiliation:
                  name:University of Oxford
                  address:
                     name:Centre for Statistics in Medicine, University of Oxford, Oxford, UK
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Lisa M McShane
            affiliation:
                  name:US National Cancer Institute
                  address:
                     name:US National Cancer Institute, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Willi Sauerbrei
            affiliation:
                  name:Universitaetsklinikum Freiburg
                  address:
                     name:Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sheila E Taube
            affiliation:
                  name:ST-Consulting
                  address:
                     name:ST-Consulting, Bethesda, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:BMC Medicine
      issn:
         1741-7015
      volumeNumber:10
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Oxford
      address:
         name:Centre for Statistics in Medicine, University of Oxford, Oxford, UK
         type:PostalAddress
      name:US National Cancer Institute
      address:
         name:US National Cancer Institute, Bethesda, USA
         type:PostalAddress
      name:Universitaetsklinikum Freiburg
      address:
         name:Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
         type:PostalAddress
      name:ST-Consulting
      address:
         name:ST-Consulting, Bethesda, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Douglas G Altman
      affiliation:
            name:University of Oxford
            address:
               name:Centre for Statistics in Medicine, University of Oxford, Oxford, UK
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Lisa M McShane
      affiliation:
            name:US National Cancer Institute
            address:
               name:US National Cancer Institute, Bethesda, USA
               type:PostalAddress
            type:Organization
      name:Willi Sauerbrei
      affiliation:
            name:Universitaetsklinikum Freiburg
            address:
               name:Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
               type:PostalAddress
            type:Organization
      name:Sheila E Taube
      affiliation:
            name:ST-Consulting
            address:
               name:ST-Consulting, Bethesda, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Centre for Statistics in Medicine, University of Oxford, Oxford, UK
      name:US National Cancer Institute, Bethesda, USA
      name:Institut fuer Medizinische Biometrie und Medizinische Informatik, Universitaetsklinikum Freiburg, Freiburg, Germany
      name:ST-Consulting, Bethesda, USA

External Links {🔗}(484)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Bootstrap
Clipboard.js
Prism.js

CDN Services {📦}

Crossref

7.42s.

LINK . SPRINGER . COM {}